Mary Finnegan, MD
Dermatology · Omaha, NENPI 1760420194
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 167 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations.
Across 167 payments — averaging $17.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$579
- Sun Pharmaceutical Industries Inc.$184
- Lilly USA, LLC$181
- LEO Pharma Inc.$165
- Incyte Corporation$164
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$151
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,79897%
- Education$973%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 38 | $579 |
| Sun Pharmaceutical Industries Inc. | 7 | $184 |
| Lilly USA, LLC | 10 | $181 |
| LEO Pharma Inc. | 8 | $165 |
| Incyte Corporation | 8 | $164 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 10 | $151 |
| E.r. Squibb & Sons, L.L.C. | 8 | $142 |
| Regeneron Healthcare Solutions, Inc. | 6 | $140 |
| Pfizer | 9 | $134 |
| Johnson & Johnson | 8 | $132 |
| Amgen | 7 | $123 |
| Novartis | 6 | $116 |
| UCB, Inc. | 7 | $114 |
| Sanofi-aventis U.S. LLC | 4 | $78 |
| Sanofi | 3 | $77 |
| Galderma Laboratories, L.p. | 5 | $76 |
| Almirall LLC | 3 | $62 |
| Arcutis Biotherapeutics, Inc. | 4 | $61 |
| Bristol Myers Squibb | 3 | $49 |
| Boehringer Ingelheim | 2 | $30 |
| Dermira, Inc. | 1 | $20 |
| Dermavant Sciences, Inc. | 2 | $18 |
| Mayne Pharma Commercial LLC | 1 | $18 |
| Botanix SB Inc | 1 | $16 |
| Blueprint Medicines Corporation | 1 | $14 |
| Biofrontera Inc. | 1 | $12 |
| Merz North America, Inc. | 1 | $12 |
| Janssen Scientific Affairs, LLC | 1 | $12 |
| Genentech USA, Inc. | 1 | $11 |
| Organon | 1 | $4 |
How this compares
$2,895 in reported general payments places this provider in the 60th percentile of 68 dermatology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 11 | $225,919 |
| Dupixent PenDupilumab | 45 | $211,020 |
| Fluorouracil | 69 | $5,043 |
| Clobetasol Propionate | 83 | $3,841 |
| Metronidazole | 58 | $3,183 |
| Doxycycline Hyclate | 150 | $3,124 |
| Betamethasone Valerate | 56 | $1,633 |
| Fluocinonide | 33 | $1,580 |
| Minoxidil | 228 | $1,535 |
| Tacrolimus | 16 | $1,429 |
| Triamcinolone Acetonide | 118 | $1,272 |
| Hydroxychloroquine Sulfate | 57 | $1,119 |
| Clindamycin Phosphate | 34 | $966 |
| Ketoconazole | 43 | $543 |
| Gabapentin | 24 | $500 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Omaha
- Rachel PersonOmaha$98K
- Erin BarrettOmaha$96K
- Joel SchlessingerOmaha$89K
- Mathew DaveyOmaha$35K
- Gage RenschOmaha$11K
- Herschel StollerOmaha$10K
- Deirdre StolmeierOmaha$10K
- Melissa DarlingOmaha$10K
- Christopher HuerterOmaha$7K
- Tina KinsleyOmaha$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.